Last updated on November 2018

Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies


Brief description of study

The primary objective of this study is to assess the safety and outcomes of infants and children who were exposed to retosiban or comparator in utero in the planned Phase III spontaneous preterm labor (SPTL) treatment studies, to provide assurance that treatment is not associated with significant adverse outcomes in early childhood. The enrolled infants and children will be followed at pre-specified intervals until they reach 5 years chronological age. This study does not require medical interventions or study visits to an investigational site, instead, parents or legal guardians will be prompted at certain time points to complete developmental questionnaires and other data on their children's health status via an electronic device. Data collected during the infant and child follow up study will be managed by a centralized research coordinating center (RCC). Regionally based pediatricians will serve as study principal investigators (referred to as RCC-PIs) for this study. All communications the RCC-PI has with the parent/legal guardian or the child's health care provider (HCP) will occur remotely; there will be no clinic visits.

Clinical Study Identifier: NCT02292784

Find a site near you

Start Over

GSK Investigational Site

Birmingham, AL United States
  Connect »

GSK Investigational Site

Jacksonville, FL United States
  Connect »

GSK Investigational Site

Maywood, IL United States
  Connect »

GSK Investigational Site

Park Ridge, IL United States
  Connect »

GSK Investigational Site

Indianapolis, IN United States
  Connect »

GSK Investigational Site

Louisville, KY United States
  Connect »

GSK Investigational Site

Bethesda, MD United States
  Connect »

GSK Investigational Site

Newark, NJ United States
  Connect »

GSK Investigational Site

Chapel Hill, NC United States
  Connect »

GSK Investigational Site

Durham, NC United States
  Connect »

GSK Investigational Site

Cleveland, OH United States
  Connect »

GSK Investigational Site

Portland, OR United States
  Connect »

GSK Investigational Site

Charleston, SC United States
  Connect »

GSK Investigational Site

Galveston, TX United States
  Connect »

GSK Investigational Site

Tacoma, WA United States
  Connect »

GSK Investigational Site

Ribeirão Preto, Brazil
  Connect »

GSK Investigational Site

Le Kremlin-Bicêtre, France
  Connect »

GSK Investigational Site

Saint-Priest en Jarez, France
  Connect »

GSK Investigational Site

Seongnam, Korea, Republic of
  Connect »

GSK Investigational Site

Seoul, Korea, Republic of
  Connect »

GSK Investigational Site

Quezon City, Philippines
  Connect »

GSK Investigational Site

Santiago de Compostela, Spain
  Connect »

GSK Investigational Site

Sunderland, United Kingdom
  Connect »

GSK Investigational Site

Coventry, United Kingdom
  Connect »

GSK Investigational Site

Glasgow, United Kingdom
  Connect »

GSK Investigational Site

Manchester, United Kingdom
  Connect »

GSK Investigational Site

Middlesbrough, United Kingdom
  Connect »

GSK Investigational Site

Newcastle Upon Tyne, United Kingdom
  Connect »

GSK Investigational Site

Nottingham, United Kingdom
  Connect »

GSK Investigational Site

Sheffield, United Kingdom
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.